- Conditions
- Leukemia, Myeloid, Acute
- Interventions
- Oral Azacitidine, Placebo
- Drug
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 55 Years and older
- Enrollment
- 472 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2024
- U.S. locations
- 60
- States / cities
- Phoenix, Arizona • Burbank, California • Duarte, California + 48 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 649–672
of 10,729
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Leukemia, Hairy Cell Leukemia, HCL
- Interventions
- Immunotoxin therapy, CAT-8015 Immunotoxin, Biological therapy
- Drug · Procedure
- Lead sponsor
- Cambridge Antibody Technology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2007
- U.S. locations
- 3
- States / cities
- Stanford, California • Chicago, Illinois • Bethesda, Maryland
- Conditions
- Eosinophilia, Angioedema
- Interventions
- mepolizumab
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Epstein-Barr Virus Infection, Infectious Mononucleosis, Herpesvirus
- Interventions
- Matrix-M1 Adjuvant, EBV gp350-Ferritin Vaccine, Placebo Comparator
- Drug · Other
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 25 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 2
- States / cities
- Bethesda, Maryland • Minneapolis, Minnesota
- Conditions
- Blood Loss, Anemia, Trauma
- Interventions
- RBC units
- Biological
- Lead sponsor
- Oregon Health and Science University
- Other
- Eligibility
- 15 Years to 100 Years
- Enrollment
- 254 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 5
- States / cities
- Cincinnati, Ohio • Portland, Oregon • Dallas, Texas + 2 more
- Conditions
- Leukemia
- Interventions
- arsenic trioxide, cytarabine, daunorubicin hydrochloride, mercaptopurine, methotrexate, tretinoin
- Drug
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 5 Years to 74 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2013
- U.S. locations
- 7
- States / cities
- Birmingham, Alabama • Gainesville, Florida • Atlanta, Georgia + 3 more
- Conditions
- Sickle Cell Disease, Executive Dysfunction, Cognitive Impairment, Attention Deficit/Hyperactivity Disorder (ADHD)
- Interventions
- Extended-Release Methylphenidate
- Drug
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Eligibility
- 8 Years to 17 Years
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- Memphis, Tennessee
- Conditions
- Acute Myelogenous Leukemia in Relapse, Acute Myelogenous Leukemia, Relapsed, Adult, Acute Myelogenous Leukemia, Adult, Acute Myelogenous Leukemia, High Risk Myelodysplasia
- Interventions
- APTO-253
- Drug
- Lead sponsor
- Aptose Biosciences Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2021
- U.S. locations
- 13
- States / cities
- Tucson, Arizona • La Jolla, California • Orange, California + 10 more
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
- Interventions
- anti-thymocyte globulin, sargramostim, therapeutic allogeneic lymphocytes, busulfan, fludarabine phosphate, methotrexate, tacrolimus, nonmyeloablative allogeneic hematopoietic stem cell transplantation, peripheral blood stem cell transplantation
- Biological · Drug · Procedure
- Lead sponsor
- UNC Lineberger Comprehensive Cancer Center
- Other
- Eligibility
- 10 Years and older
- Enrollment
- 71 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Anemia, Breast Cancer, Chronic Myeloproliferative Disorders, Drug/Agent Toxicity by Tissue/Organ, Leukemia, Lung Cancer, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Precancerous Condition, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- epoetin alfa, placebo
- Biological · Other
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 344 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2010
- U.S. locations
- 20
- States / cities
- Scottsdale, Arizona • Washington D.C., District of Columbia • Peoria, Illinois + 17 more
- Conditions
- Chronic Myelogenous Leukemia
- Interventions
- Chart Review
- Other
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- Not listed
- Enrollment
- 3,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2030
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Iron-deficiency, Iron Deficiency Anemia, Iron Deficiency Anemia Treatment
- Interventions
- Iron supplement with a lunch meal containing beef, Iron supplement with a lunch meal containing plant-based alternative
- Other
- Lead sponsor
- Pennington Biomedical Research Center
- Other
- Eligibility
- 18 Years to 40 Years · Female only
- Enrollment
- 59 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2024
- U.S. locations
- 1
- States / cities
- Baton Rouge, Louisiana
- Conditions
- Acute Lymphoblastic Leukemia
- Interventions
- Wearable Sensors
- Other
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Eligibility
- 5 Years to 25 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Memphis, Tennessee
- Conditions
- Multiple Myeloma, Plasma Cell Neoplasm, Thromboembolism
- Interventions
- enzyme-linked immunosorbent assay, laboratory biomarker analysis, medical chart review
- Other
- Lead sponsor
- UNC Lineberger Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2016
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Anemia, Sickle Cell
- Interventions
- NP Battery, MRI
- Behavioral · Procedure
- Lead sponsor
- UCSF Benioff Children's Hospital Oakland
- Other
- Eligibility
- 21 Years to 55 Years
- Enrollment
- 212 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2004 – 2008
- U.S. locations
- 12
- States / cities
- Los Angeles, California • Oakland, California • Hollywood, Florida + 8 more
- Conditions
- Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Lymphoproliferative Disorder, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Pain, Precancerous Condition, Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- methadone hydrochloride, morphine sulfate, oxycodone hydrochloride
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 2
- States / cities
- Spartanburg, South Carolina • Houston, Texas
- Conditions
- Relapsed or Refractory Multiple Myeloma
- Interventions
- SIM0500
- Drug
- Lead sponsor
- Jiangsu Simcere Pharmaceutical Co., Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 130 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 9
- States / cities
- Phoenix, Arizona • Orange, California • Jacksonville, Florida + 5 more
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Cytarabine, Mitoxantrone Hydrochloride, Selinexor
- Drug
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- Not listed
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Lymphoma
- Interventions
- rituximab, dexamethasone
- Biological · Drug
- Lead sponsor
- Hoag Memorial Hospital Presbyterian
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2000
- U.S. locations
- 3
- States / cities
- Newport Beach, California • Bloomington, Indiana • Bryan, Texas
- Conditions
- Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, Acute Leukemia, Chronic Myeloid Leukemia
- Interventions
- CD8+ Memory T Cell Infusion, Thiotepa, Fludarabine, Hyperfractionated TBI, Busulfan, Cyclophosphamide
- Drug · Radiation
- Lead sponsor
- Robert Lowsky
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 7 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2023
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
- Interventions
- Imipenem/Cilastatin/Relebactam, Cefepime, Meropenem, Piperacillin-Tazobactam, Vancomycin, Daptomycin, Linezolid
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Myeloproliferative Disease, Myelofibrosis, Idiopathic Myelofibrosis, Essential Thrombocythemia, Polycythemia Vera
- Interventions
- Not listed
- Lead sponsor
- Icahn School of Medicine at Mount Sinai
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 592 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2018
- U.S. locations
- 15
- States / cities
- Scottsdale, Arizona • Palo Alto, California • Washington D.C., District of Columbia + 10 more
- Conditions
- Chronic Primary Immune Thrombocytopenia (ITP)
- Interventions
- Kedrion IVIG 10%
- Biological
- Lead sponsor
- Kedrion S.p.A.
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 3
- States / cities
- Los Angeles, California • Shirley, New York • Greenville, North Carolina
- Conditions
- Anemia, Recurrent Multiple Myeloma, Refractory Multiple Myeloma
- Interventions
- Carfilzomib, Dexamethasone, Laboratory Biomarker Analysis, Pelareorep
- Drug · Other · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2024
- U.S. locations
- 3
- States / cities
- Atlanta, Georgia • Columbus, Ohio • Salt Lake City, Utah